Listen to Dr. Kelly McCann to learn about the BRIA-ABC clinical trial, a Phase 3 study evaluating a novel immunotherapy approach for patients with advanced metastatic or locally recurrent breast cancer. This multicenter, randomized, open-label trial compares three groups: one receiving Bria-IMT—a whole-cell cancer vaccine—combined with retifanlimab, an immune checkpoint inhibitor; a second group receiving Bria-IMT alone; and a third group receiving a treatment of physician’s choice. The primary goal is to determine whether Bria-IMT, alone or in combination with retifanlimab, can improve overall survival compared to existing treatments. This program will provide an overview of the trial, the science behind the therapy, and information on how patients can learn more or get involved.
Link to Trial: http://breastcancertrials.org/bct_nation/mts/mtsResult.seam?zip=94107&yob=0&searchTerm1=NCT06072612#trialtitle
